Fujian Aonong Biological Technology Group Incorporation Ltd (603363) - Net Assets
Based on the latest financial reports, Fujian Aonong Biological Technology Group Incorporation Ltd (603363) has net assets worth CN¥3.34 Billion CNY (≈ $489.04 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.81 Billion ≈ $1.29 Billion USD) and total liabilities (CN¥5.47 Billion ≈ $800.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603363 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.34 Billion |
| % of Total Assets | 37.92% |
| Annual Growth Rate | 34.05% |
| 5-Year Change | 63.26% |
| 10-Year Change | 502.98% |
| Growth Volatility | 79.2 |
Fujian Aonong Biological Technology Group Incorporation Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Fujian Aonong Biological Technology Group Incorporation Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Fujian Aonong Biological Technology Grou stock valuation.
Annual Net Assets for Fujian Aonong Biological Technology Group Incorporation Ltd (2013–2025)
The table below shows the annual net assets of Fujian Aonong Biological Technology Group Incorporation Ltd from 2013 to 2025. Also explore Fujian Aonong Biological Technology Grou net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.58 Billion ≈ $523.90 Million |
+16.96% |
| 2024-12-31 | CN¥3.06 Billion ≈ $447.94 Million |
+708.32% |
| 2023-12-31 | CN¥-503.22 Million ≈ $-73.64 Million |
-114.66% |
| 2022-12-31 | CN¥3.43 Billion ≈ $502.21 Million |
+56.50% |
| 2021-12-31 | CN¥2.19 Billion ≈ $320.90 Million |
-43.82% |
| 2020-12-31 | CN¥3.90 Billion ≈ $571.16 Million |
+204.09% |
| 2019-12-31 | CN¥1.28 Billion ≈ $187.83 Million |
+27.22% |
| 2018-12-31 | CN¥1.01 Billion ≈ $147.64 Million |
+4.49% |
| 2017-12-31 | CN¥965.55 Million ≈ $141.29 Million |
+62.62% |
| 2016-12-31 | CN¥593.75 Million ≈ $86.88 Million |
+33.31% |
| 2015-12-31 | CN¥445.39 Million ≈ $65.17 Million |
+107.21% |
| 2014-12-31 | CN¥214.94 Million ≈ $31.45 Million |
+102.10% |
| 2013-12-31 | CN¥106.35 Million ≈ $15.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fujian Aonong Biological Technology Group Incorporation Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28530.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥8.10 Billion | 258.66% |
| Total Equity | CN¥3.13 Billion | 100.00% |
Fujian Aonong Biological Technology Group Incorporation Ltd Competitors by Market Cap
The table below lists competitors of Fujian Aonong Biological Technology Group Incorporation Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Ringpu Bio Tech
SHE:300119
|
$1.17 Billion |
|
MRC Global Inc
NYSE:MRC
|
$1.17 Billion |
|
Marcus & Millichap Inc
NYSE:MMI
|
$1.17 Billion |
|
TF Bank AB
ST:TFBANK
|
$1.17 Billion |
|
Maoye Commercial Co Ltd
SHG:600828
|
$1.17 Billion |
|
Guangdong South New Media Co Ltd
SHE:300770
|
$1.17 Billion |
|
Avanos Medical Inc
NYSE:AVNS
|
$1.17 Billion |
|
Goldcup Electric Apparatus Co Ltd
SHE:002533
|
$1.17 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fujian Aonong Biological Technology Group Incorporation Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,566,181,540 to 3,130,473,782, a change of 564,292,242 (22.0%).
- Net income of 77,621,595 contributed positively to equity growth.
- Dividend payments of 84,505,769 reduced retained earnings.
- Other comprehensive income decreased equity by 95,985,620.
- Other factors increased equity by 667,162,036.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥77.62 Million | +2.48% |
| Dividends Paid | CN¥84.51 Million | -2.7% |
| Other Comprehensive Income | CN¥-95.99 Million | -3.07% |
| Other Changes | CN¥667.16 Million | +21.31% |
| Total Change | CN¥- | 21.99% |
Book Value vs Market Value Analysis
This analysis compares Fujian Aonong Biological Technology Group Incorporation Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.44x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 13.74x to 2.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.21 | CN¥2.93 | x |
| 2014-12-31 | CN¥0.39 | CN¥2.93 | x |
| 2015-12-31 | CN¥0.79 | CN¥2.93 | x |
| 2016-12-31 | CN¥1.00 | CN¥2.93 | x |
| 2017-12-31 | CN¥1.67 | CN¥2.93 | x |
| 2018-12-31 | CN¥1.45 | CN¥2.93 | x |
| 2019-12-31 | CN¥1.52 | CN¥2.93 | x |
| 2020-12-31 | CN¥4.35 | CN¥2.93 | x |
| 2021-12-31 | CN¥2.37 | CN¥2.93 | x |
| 2022-12-31 | CN¥3.23 | CN¥2.93 | x |
| 2023-12-31 | CN¥-1.11 | CN¥2.93 | x |
| 2024-12-31 | CN¥2.97 | CN¥2.93 | x |
| 2025-12-31 | CN¥1.20 | CN¥2.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fujian Aonong Biological Technology Group Incorporation Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.92%
- • Asset Turnover: 0.97x
- • Equity Multiplier: 2.79x
- Recent ROE (2.48%) is above the historical average (-0.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 26.69% | 0.85% | 4.16x | 7.59x | CN¥15.63 Million |
| 2014 | 25.05% | 1.02% | 4.51x | 5.43x | CN¥25.68 Million |
| 2015 | 8.86% | 0.84% | 2.98x | 3.54x | CN¥-4.33 Million |
| 2016 | 19.31% | 1.84% | 2.91x | 3.62x | CN¥44.06 Million |
| 2017 | 13.37% | 2.21% | 1.93x | 3.14x | CN¥27.27 Million |
| 2018 | 3.70% | 0.52% | 1.74x | 4.06x | CN¥-51.25 Million |
| 2019 | 3.52% | 0.50% | 1.18x | 5.94x | CN¥-53.65 Million |
| 2020 | 20.90% | 4.98% | 0.96x | 4.38x | CN¥298.78 Million |
| 2021 | -116.60% | -8.43% | 1.05x | 13.12x | CN¥-1.65 Billion |
| 2022 | -41.47% | -4.80% | 1.16x | 7.45x | CN¥-1.29 Billion |
| 2023 | 0.00% | -18.76% | 1.43x | 0.00x | CN¥-3.55 Billion |
| 2024 | 22.58% | 6.61% | 0.92x | 3.70x | CN¥322.73 Million |
| 2025 | 2.48% | 0.92% | 0.97x | 2.79x | CN¥-235.43 Million |
Industry Comparison
This section compares Fujian Aonong Biological Technology Group Incorporation Ltd's net assets metrics with peer companies in the Farm Products industry.
Industry Context
- Industry: Farm Products
- Average net assets among peers: $3,142,490,293
- Average return on equity (ROE) among peers: 18.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fujian Aonong Biological Technology Group Incorporation Ltd (603363) | CN¥3.34 Billion | 26.69% | 1.64x | $1.17 Billion |
| ShenZhen Kondarl Group Co Ltd (000048) | $443.44 Million | 108.93% | 1.84x | $1.51 Billion |
| Guangdong Guanghong Holdings Co Ltd (000529) | $3.17 Billion | 6.71% | 1.21x | $429.70 Million |
| Hunan Zhenghong Science and Technology Develop Co Ltd (000702) | $460.77 Million | 1.06% | 0.36x | $293.68 Million |
| Hefei Fengle Seed Co Ltd (000713) | $1.34 Billion | 4.53% | 0.40x | $793.10 Million |
| Luoniushan Co Ltd (000735) | $1.64 Billion | 3.72% | 0.49x | $1.01 Billion |
| New Hope Liuhe Co Ltd (000876) | $14.49 Billion | 11.78% | 0.70x | $4.76 Billion |
| Yuan Longping High-tech Agriculture Co Ltd (000998) | $8.02 Billion | 1.42% | 1.98x | $1.94 Billion |
| Dongrui Food Group Co Ltd (001201) | $160.11 Million | 12.03% | 1.52x | $614.87 Million |
| Jiangxi Sunshine Dairy Co Ltd (001318) | $1.41 Billion | 8.10% | 0.05x | $489.31 Million |
| Shandong Denghai Seeds Co Ltd (002041) | $279.21 Million | 30.58% | 0.68x | $1.35 Billion |
About Fujian Aonong Biological Technology Group Incorporation Ltd
Fujian Aonong Biological Technology Group Incorporation Limited engages in the feed, pig farming, food, supply chain services, and other businesses in China and internationally. It researches and develops, produces, and sells feed products, such as pig feed, poultry feed, aquatic feed, ruminant, and other products; and operates pig breeding farms. The company also engages in the pig slaughtering … Read more